Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats

European Journal of Pharmacology

Volumn 551, Issue 1-3, 2006, Pages 58-66

  Kumar, Anil ^a   Seghal, Neha ^a   Padi, Satyanaryana Venketeshwara ^a   Naidu, Pattipati Sreenivaslu ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Alzheimer's disease; Antioxidant; Cognitive impairment; Colchicine; Cyclooxygenase inhibitor; Oxidative stress

Indexed keywords

ACETYLCHOLINESTERASE; BIOLOGICAL MARKER; COLCHICINE; FREE RADICAL; GLUTATHIONE; MALONALDEHYDE; NAPROXEN; NITRITE; PROSTAGLANDIN SYNTHASE INHIBITOR; VALDECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DEPLETION; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GLUTATHIONE METABOLISM; LONG TERM EXPOSURE; LONG TERM MEMORY; MALE; MAZE TEST; MEMORY CONSOLIDATION; MEMORY DISORDER; MENTAL PERFORMANCE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ACETYLCHOLINESTERASE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; COGNITION DISORDERS; COLCHICINE; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; INJECTIONS, INTRAVENTRICULAR; ISOXAZOLES; LIPID PEROXIDATION; MALE; MAZE LEARNING; MEMORY; NAPROXEN; NITRITES; OXIDATIVE STRESS; RATS; RATS, WISTAR; SPACE PERCEPTION; SPATIAL BEHAVIOR; SULFONAMIDES; TIME FACTORS;

EID: 33750488783     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.076     Document Type: Article

References (48)

1. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., and Thal L.J. Alzheimer's disease cooperative study. Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA 289 (2003) 2819-2826
2. Asanuma M., Nishibayashi-Asanuma S., Miyazaki I., Kohno M., and Ogawa N. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J. Neurochem. 76 (2001) 1895-1904
3. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative disease. Ann. Neurol. 38 (1995) 357-366
4. Bezzi P., Carmignoto G., Pasti L., Vesce S., Rossi D., Rizzini B.L., Pozzan T., and Volterra A. Prostaglandins stimulate calcium dependent glutamate release in astrocytes. Nature 39 (1998) 281-285
5. Bondy C.S. The relation of oxidative stress and hyperexcitation to neurological disease. Proc. Soc. Exp. Biol. Med. 208 (1995) 337-345
6. Breder C.D., Dewitt D., and Kraig R.P. Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol. 355 (1995) 296-315
7. Bruce-Keller A.J., Li Y.J., Lovell M.A., Kraemer P.J., Gary D.S., Brown R.R., Markesbery W.R., and Mattson M.P. 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats. J. Neuropathol. Exp. Neurol. 57 (1998) 257-267
8. Candelario-Jalil E., Gonzalez-Falcon A., Garcia-Cabrera M., Alvarez D., Al-Dalain S., Martinez G., Leon O.S., and Springer J.E. Assessment of the relative contribution of cyclooxygenase-1 and cyclooxygenase-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J. Neurochem. 86 (2003) 545-555
9. Costa D., Gomes A., Reis S., Lima J.L., and Fernades E. Hydrogen peroxide scavenging activity of NSAIDs. Life Sci. 76 (2005) 2841-2848
10. Cui J.G., Kuroda H., Chandrasekharan N.V., Pelaez R.P., Simmons D.L., Bazan N.G., and Lukiw W.J. Cyclooxygenase-3 gene expression in Alzheimer hippocampus and in stressed human neural cells. Neurochem. Res. 29 (2004) 1731-1737
11. Dawson Jr. R., Beal M.F., Bondy S.C., Di Monte D.A., and Isom G.E. Excitotoxins, aging and environmental neurotoxins: implications for understanding human neurodegenerative diseases. Toxicol. Appl. Pharmacol. 134 (1995) 1-17
12. Ellman G.L., Courtney K.D., Andres V., and Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961) 88-95
13. Emerich D.F., and Walsh T.J. Cholinergic loss and cognitive impairment following intraventricular or intradentate injections of colchicine. Brain Res. 517 (1990) 157-167
14. Etminan M., Gill S., and Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Br. Med. J. 327 (2003) 128
15. Fass U., Panickar K., Personett D., Bryan D., Williams K., Gonzales J., Sugaya K., and McKinney M. Differential vulnerability of primary cultured cholinergic neurons to nitric oxide excess. NeuroReport 11 (2003) 931-936
16. Goodwin D.C., Landino L.M., and Marnett L.J. Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. FASEB J. 13 (1999) 1121-1136
17. Greco A., Minghetti L., and Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem. Res. 25 (2000) 1357-1364
18. Green L.C., Wagner D.A., Glgowski J., Skipper P.L., Wishnok J.S., and Tannebaum S.R. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Ann. Biochem. Exp. Med. 126 (1982) 131-135
19. Ho L., Osaka H., Aisen P.S., and Pasinetti G.M. Induction of cyclooxygenase-2 but not cyclooxygenase-1 gene expression in apoptotic cell death. J. Neuroimmunol. 89 (1998) 142-149
20. In t' Veld B.A., Ruitenberg A., Hofman A., Launer L.J., Van Duijn C.M., Stijnen T., Breteler M.M., and Stricker B.H. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345 (2001) 1515-1521
21. Jain N.K., Patil C.S., Kulkarni S.K., and Singh A. Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice. Behav. Brain Res. 133 (2002) 369-376
22. Kaufmann W.E., Worley P.F., Taylor C.V., Bremer M., and Isakson P. Cyclooxygenase-2, a synaptically induced enzyme is expressed by excitatory neurons at post-synaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 2317-2321
23. Kaufmann W.E., Anderson K.I., Isakson P.C., and Worley P.F. Cyclooxygenase and the central nervous system. Prostaglandins 54 (1997) 601-624
24. Kitamura Y., Shimohama S., Koike H., Kakimura J., Matsuoka Y., Nomura Y., Gebicke-Haerter P.J., and Taniguchi T. Increased expression of cyclooxygenase and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 254 (1999) 582-586
25. Kukreja R.C., Kontes H.A., Hess M.L., and Ellis E.F. PGH synthase and lipooxygenase generate superoxide in the presence of NADH or NADPH. Circ. Res. 59 (1986) 612-619
26. Kumar V., and Gupta Y.K. Intracerebroventricular administration of colchicine produces cognitive impairment associated with oxidative stress in rats. Pharmacol. Biochem. Behav. 73 (2002) 565-571
27. Leist M., Volbracht C., Kuhnle S., Fava E., Ferrando May E., and Nicotera P. Caspase-mediated apoptosis in neuronal excitotoxicity triggered by nitric oxide. Mol. Med. 3 (1997) 750-764
28. Madrigal J.L., Garcia-Bueno B., Moro M.A., Lizasoain I., Lorenzo P., and Leza J.C. Relationship between cyclooxygenase-2 and nitric oxide synthase-2 in rat cortex after stress. Eur. J. Neurosci. 18 (2003) 1701-1705
29. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23 (1999) 134-147
30. Matsumoto Y., Yamaguchi T., Watanabe S., and Yamamoto T. Involvement of arachidonic acid cascade in working memory impairment induced by interleukin-1 beta. Neuropharmacology 46 (2004) 1195-1200
31. 2 levels in patients with probable Alzheimer's disease. Neurology 53 (1999) 195-198
32. Moore A.H., and O'Banion M.K. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv. Drug Deliv. Rev. 54 (2002) 1627-1656
33. Nakagawa Y.S., Nakamura S., Kase Y., Noguchi T., and Ishihara T. Colchicine lesions in the rat hippocampus mimic the alterations of several markers in Alzheimer's disease. Brain Res. 408 (1987) 57-64
34. Nogawa S., Zhang F., Ross M.E., and Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. 17 (1997) 2746-2755
35. Pasinetti G.M., and Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87 (1998) 319-324
36. Pepicelli O., Fedele E., Bonanno G., Raiteri M., Ajmone-Cat M.A., Greco A., Levi G., and Minghetti L. In vivo activation of N-methyl-d-aspartate receptors in the rat hippocampus increases prostaglandin E (2) extracellular levels and triggers lipid peroxidation through cyclooxygenase-mediated mechanisms. J. Neurochem. 81 (2002) 1028-1034
37. Qin W., Ho L., Pompl P.N., Peng Y., Zhao Z., Xiang Z., Robakis N.K., Shioi J., Suh J., and Pasinetti G.M. Cyclooxygenase-2 and cyclooxygenase-1 potentiates beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J. Biol. Chem. 278 (2003) 50970-50977
38. Riccerin L., Minghetti L., Moles A., Popoli P., Confaloni A., De Simone R., Piscopo P., Scattoni M.L., di Luca M., and Calamandrei G. Cognitive and neurological deficits induced by early and prolonged basal forebrain cholinergic hypofunction in rats. Exp. Neurol. 189 (2004) 162-172
39. Salzberg-Brenhouse H.C., Chen E.Y., Emerich D.F., Baldwin S., Hogeland K., Ranelli S., Lafreniere D., Perdomo B., Novak L., Kladis T., Fu K., Basile A.S., Kordower J.H., and Bartus R.T. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. J. Pharmacol. Exp. Ther. 306 (2003) 218-228
40. Scali C., Giovannini M.G., Prosperi C., Bellucci A., Pepeu G., and Casamenti F. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience 117 (2003) 909-919
41. Shaw K.N., Commins S., and O'Mara S.M. Cyclooxygenase inhibition attenuates endotoxin-induced spatial learning deficits, but not an endotoxin-induced blockade of long-term potentiation. Brain Res. 1038 (2005) 231-237
42. Sinclair A.J., Bayer A.J., Johnston J., Warner C., and Maxweel S.R. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int. J. Geriatr. Psychiatry 13 (1998) 840-845
43. Strauss K.I., and Marini A.M. Cyclooxygenase-2 inhibition protects cultured cerebellar granule neurons from glutamate-mediated cell death. J. Neurotrauma 19 (2002) 627-638
44. Stuchbury G., and Munch G. Alzheimer's associated inflammation, potential drug targets and future therapies. J. Neural Transm. 112 (2005) 429-453
45. Subbaramaiah K., Hart J.C., Norton L., and Dannenberg A.J. Microtubule interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK 1/2 and p38 mitogen-activated protein kinase pathways. J. Biol. Chem. 275 (2002) 14838-14845
46. Verma A., and Kulkarni S.K. Evaluation of learning and memory mechanisms employing plus maze in rats and mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 16 (1992) 117-125
47. Wills E.D. Mechanism of lipid peroxide formation in animal. Biochem. J. 99 (1996) 667-676
48. Yu Z., Cheng G., and Hu B. Mechanism of colchicine impairment on learning and memory, and protective effect of CGP36742 in mice. Brain Res. 750 (1997) 53-58